Pharvaris, N.V (PHVS)
| Market Cap | 675.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 33.13M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $20.38 |
| Previous Close | $20.06 |
| Change ($) | 0.32 |
| Change (%) | 1.60% |
| Day's Open | 20.88 |
| Day's Range | 19.96 - 20.78 |
| Day's Volume | 7,977 |
| 52-Week Range | 19.29 - 42.86 |
ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
ZUG, Switzerland, May 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists fo...
ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...
ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the t...
Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers
ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
ZUG, Switzerland-- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery,...
Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema.
Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Pharvaris, N.V has filed to go public with an IPO on the NASDAQ.
About PHVS
Pharvaris is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Our first molecule, PHA121, is a novel, small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema, or HAE. Bradykinin-B2-receptor inhibition is a clinically validated mechanism for the treatment of HAE. We designed PHA121 to improve upon the therapeutic profile of ex... [Read more...]
| Industry Biotechnology | IPO Date Feb 5, 2021 |
| CEO Berndt Modig | Employees 14 |
| Stock Exchange NASDAQ | Ticker Symbol PHVS |